JP2022551269A5 - - Google Patents

Info

Publication number
JP2022551269A5
JP2022551269A5 JP2022520472A JP2022520472A JP2022551269A5 JP 2022551269 A5 JP2022551269 A5 JP 2022551269A5 JP 2022520472 A JP2022520472 A JP 2022520472A JP 2022520472 A JP2022520472 A JP 2022520472A JP 2022551269 A5 JP2022551269 A5 JP 2022551269A5
Authority
JP
Japan
Prior art keywords
nucleotides
modified
positions
oligonucleotide according
antisense
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2022520472A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022551269A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/053999 external-priority patent/WO2021067744A1/en
Publication of JP2022551269A publication Critical patent/JP2022551269A/ja
Publication of JP2022551269A5 publication Critical patent/JP2022551269A5/ja
Withdrawn legal-status Critical Current

Links

JP2022520472A 2019-10-02 2020-10-02 最小フッ素含有量を用いた低分子干渉rnaの化学修飾 Withdrawn JP2022551269A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962909278P 2019-10-02 2019-10-02
US62/909,278 2019-10-02
PCT/US2020/053999 WO2021067744A1 (en) 2019-10-02 2020-10-02 Chemical modifications of small interfering rna with minimal fluorine content

Publications (2)

Publication Number Publication Date
JP2022551269A JP2022551269A (ja) 2022-12-08
JP2022551269A5 true JP2022551269A5 (cg-RX-API-DMAC7.html) 2023-10-25

Family

ID=73038388

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022520472A Withdrawn JP2022551269A (ja) 2019-10-02 2020-10-02 最小フッ素含有量を用いた低分子干渉rnaの化学修飾

Country Status (12)

Country Link
US (2) US20220389430A1 (cg-RX-API-DMAC7.html)
EP (1) EP4038191A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022551269A (cg-RX-API-DMAC7.html)
KR (1) KR20220069103A (cg-RX-API-DMAC7.html)
CN (1) CN114761557B (cg-RX-API-DMAC7.html)
AU (1) AU2020358016A1 (cg-RX-API-DMAC7.html)
CA (1) CA3153026A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022000825A1 (cg-RX-API-DMAC7.html)
IL (1) IL291841A (cg-RX-API-DMAC7.html)
MX (1) MX2022004032A (cg-RX-API-DMAC7.html)
TW (1) TW202126809A (cg-RX-API-DMAC7.html)
WO (1) WO2021067744A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023012048A (es) 2021-04-12 2023-10-23 Boehringer Ingelheim Int Composiciones y metodos para inhibir cetohexoquinasa (khk).
KR20230171431A (ko) * 2021-04-14 2023-12-20 다이서나 파마수이티컬, 인크. Pnpla3 발현을 조절하기 위한 조성물 및 방법
CN117580953B (zh) * 2021-07-16 2025-07-18 苏州瑞博生物技术股份有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
CA3233113A1 (en) * 2021-09-22 2023-03-30 Sanegene Bio Usa Inc. 2'-alkyl or 3'-alkyl modified ribose derivatives for use in the in-vivo delivery of oligonucleotides
WO2023069495A1 (en) * 2021-10-19 2023-04-27 Alnylam Pharmaceuticals, Inc. Oligonucleotides with 2'-deoxy-2'-f-2'-c-methyl nucleotides
JP7877458B2 (ja) 2021-12-01 2026-06-22 ディセルナ ファーマシューティカルズ インコーポレイテッド Apoc3発現を調節するための組成物及び方法
TW202400790A (zh) * 2022-04-26 2024-01-01 大陸商上海拓界生物醫藥科技有限公司 氘代化學修飾和包含其的寡核苷酸
TW202430637A (zh) 2022-11-16 2024-08-01 美商戴瑟納製藥股份有限公司 Stat3靶向性寡核苷酸及其用途
KR20260089666A (ko) * 2023-09-14 2026-06-15 아이오니스 파마수티컬즈, 인코포레이티드 Apociii 발현을 감소시키기 위한 화합물 및 방법
WO2025191337A2 (en) * 2024-03-11 2025-09-18 Synerk Biotech Limited Oligonucleotide terminal phosphate derivatives and method of use
WO2026056961A1 (zh) * 2024-09-12 2026-03-19 瑞典瑞博科尔制药公司 寡核苷酸、寡核苷酸缀合物及组合物和用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100523215C (zh) 2000-12-01 2009-08-05 马普科技促进协会 介导rna干涉的小rna分子
WO2003040395A2 (en) 2001-11-07 2003-05-15 Applera Corporation Universal nucleotides for nucleic acid analysis
US20070265220A1 (en) 2004-03-15 2007-11-15 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
WO2007030167A1 (en) 2005-09-02 2007-03-15 Nastech Pharmaceutical Company Inc. Modification of double-stranded ribonucleic acid molecules
WO2010033225A2 (en) 2008-09-22 2010-03-25 Dicerna Pharmaceuticals, Inc. Compositions and methods for the specific inhibition of gene expression by dsrna possessing modifications
WO2010039543A2 (en) 2008-09-23 2010-04-08 Traversa Therapeutics, Inc. Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating rna interference
KR20110110776A (ko) 2008-12-18 2011-10-07 다이서나 파마수이티컬, 인크. 유전자 발현의 특이적 억제를 위한 연장된 다이서 기질 제제 및 방법
WO2010093788A2 (en) 2009-02-11 2010-08-19 Dicerna Pharmaceuticals, Inc. Multiplex dicer substrate rna interference molecules having joining sequences
US8927513B2 (en) 2009-07-07 2015-01-06 Alnylam Pharmaceuticals, Inc. 5′ phosphate mimics
US9725479B2 (en) 2010-04-22 2017-08-08 Ionis Pharmaceuticals, Inc. 5′-end derivatives
EP2928877B1 (en) 2012-12-06 2020-01-22 Merck Sharp & Dohme Corp. Disulfide masked prodrug compositions and methods
CN107109405A (zh) 2014-06-06 2017-08-29 索尔斯蒂斯生物有限公司 具有生物可逆性和非生物可逆性基团的多核苷酸构建体
EP3865576A1 (en) 2014-12-15 2021-08-18 Dicerna Pharmaceuticals, Inc. Ligand-modified double-stranded nucleic acids
HRP20231063T1 (hr) * 2017-10-13 2023-12-22 Novo Nordisk Health Care Ag Postupci i pripravci namijenjeni inhibiranju eksprimiranja ldha
EP3684377B1 (en) * 2017-10-20 2022-12-07 Dicerna Pharmaceuticals, Inc. Methods for treating hepatitis b infection

Similar Documents

Publication Publication Date Title
TWI823866B (zh) 用於抑制類血管生成素蛋白-3(ANGPTL3)表現的RNAi藥劑及組合物及使用方法
CN113164509B (zh) 用于抑制17β-HSD 13型(HSD17B13)表达的RNAi试剂、其组合物和使用方法
KR102473431B1 (ko) 안티센스 핵산
ES2318106T3 (es) Oligonucleotidos que comprenden segmentos alternos y usos de los mismos.
US20260125682A1 (en) Chemical modifications of small interfering rna with minimal fluorine content
CN110832077B (zh) 用于抑制α-ENaC表达的RNAi剂及使用方法
TW202307207A (zh) 用於抑制黃嘌呤脫氫酶(XDH)之表現之RNAi藥劑、其醫藥組合物及使用方法
CN115397436A (zh) 用于抑制PNPLA3表达的RNAi剂、其药物组合物和使用方法
JP2024505035A (ja) 中枢神経系における遺伝子発現を阻害するための組成物および方法
JP2018109015A (ja) 三環ヌクレオシドおよびこれらから調製したオリゴマー化合物
TW202334416A (zh) 用於抑制基質金屬蛋白酶7 (MMP7)之表現的RNAi藥劑、其組成物及使用方法
WO2017040271A1 (en) Modified antisense oligomers for exon inclusion in spinal muscular atrophy
JP2025522429A (ja) 中枢神経系組織への治療薬の送達のための脂質結合体
US20260049309A1 (en) Regulation of activity of rnai molecules
CN111212909A (zh) 用于抑制去唾液酸糖蛋白受体1的表达的RNAi试剂和组合物
WO2020181130A2 (en) Polynucleotide conjugates and uses thereof
WO2023011360A1 (zh) 一种增强核酸药物缓释能力的方法
JP2022520653A5 (cg-RX-API-DMAC7.html)
CN121127248A (zh) 用于抑制线粒体偕胺肟还原组分1 (MARC1)表达的RNAi剂、其药用组合物及使用方法
JP6826984B2 (ja) アシル−アミノ−lnaオリゴヌクレオチドおよび/またはヒドロカルビル−アミノ−lnaオリゴヌクレオチド
EP4219717A2 (en) Exon skipping oligomers for muscular dystrophy
WO2024233864A2 (en) Galnac-conjugated rnai oligonucleotides
TW202430635A (zh) 用於抑制補體成分C3(C3)表現之RNAi藥劑、其醫藥組合物及使用方法
HK40084771B (en) RNAi AGENTS FOR INHIBITING EXPRESSION OF PNPLA3, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE
HK40084771A (en) Rnai agents for inhibiting expression of pnpla3, pharmaceutical compositions thereof, and methods of use